M.D. Anderson Cancer Center
To study the safety and possible side effects of using the imaging agent 4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN) in PET/CT scans for participants with chronic GVHD.
Primary Objective: Determine the spatial and temporal correlation between \[18F\]4FN PET/CT measurements and the clinical manifestations and severity of GVHD. We hypothesize that \[18F\]4FN PET/CT imaging features will anatomically and by intensity (SUV) correlate with concurrent GVHD manifestations. We also hypothesize that PET/CT imaging features will temporally precede GVHD manifestations at target anatomic locations. Secondary Objective: Identify the \[18F\]4FN PET/CT-positive GVHD lesions responsive to GVHD therapies. As a pharmacodynamic biomarker, we hypothesize that changes in \[18F…
Eligibility Criteria 1. Acute or Chronic GVHD - acute and chronic GVHD criteria can be found at (Harris, Young et al. 2016)(Jagasia, et al. 2015). 2. Able to give written informed consent. 3. ≥18 years of age 4. Creatinine clearance ≥ 30 mL/min/1.73m2 5. Subjects may be planned to receive a new systemic therapy for GVHD 6. Prior / continuing systemic therapy for acute or chronic GVHD is allowed 7. KPS ≥ 20 8. Ability to understand and the willingness to sign a written informed consent document. 9. The effects of the study agent on the developing human fetus are unknown. For this reason, women…
Given by IV
Imaging
Arctuva estimate
Verify or correct the compensation shown for this listing.